A5082461875- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Retinoids in leukemia and cellular processes
- Neutropenia and Cancer Infections
- Kruppel-like factors research
- Viral Infectious Diseases and Gene Expression in Insects
- Chemotherapy-induced cardiotoxicity and mitigation
- Brain Metastases and Treatment
- Cardiovascular Function and Risk Factors
- Lymphoma Diagnosis and Treatment
- Hematological disorders and diagnostics
- Bone and Joint Diseases
- Coenzyme Q10 studies and effects
- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Cancer Immunotherapy and Biomarkers
- Acute Lymphoblastic Leukemia research
Icahn School of Medicine at Mount Sinai
2022-2024
Mount Sinai Hospital
2020-2024
Mount Sinai Hospital
2023
Memorial Sloan Kettering Cancer Center
2021
Albany College of Pharmacy and Health Sciences
2019
Although relatively rare, acute myeloid leukemia (AML) is the most common type of in adults. AML associated with poor 5-year overall survival and prompt treatment critical. Classifying based on World Health Organization criteria important for determining prognosis applying a risk-adapted approach. Throughout therapy, patients require comprehensive supportive care measures blood product transfusions, antimicrobial treatment, frequent monitoring chemotherapy-related complications. This article...
We report the first case of pacritinib-withdrawal syndrome with in vitro elucidation underlying mechanisms.
Ruxolitinib has been the cornerstone of pharmacologic therapy for myelofibrosis over a decade. However, last several years have witnessed regulatory approval other Janus kinase (JAK) inhibitors myelofibrosis, i.e. fedratinib, pacritinib, and US momelotinib is widely anticipated in 2023.Due to multifaceted clinical presentation watertight definition ruxolitinib failure remained elusive, as "progression" on can take many forms management highly nuanced. Yet, availability JAK potential future...
AbstractWe evaluated outcomes of AML patients with central nervous system (CNS) involvement at two academic institutions. Fifty-two adult were identified. Neurologic symptoms reported in 69% patients, headache the most common (33%). 84% (n = 42) cleared their cerebrospinal fluid (CSF), a median number one dose intrathecal (IT) chemotherapy. Of these 21% 9) had CSF relapse, 67% 6) those experiencing relapse also having concurrent bone marrow relapse. 36 baseline neurologic symptoms,...
Introduction Anthracycline-based chemotherapy regimens are associated with decreased cardiac function cumulative dosing, yet there is limited information regarding the acute cardiotoxic potential of these medications and appropriate medical management strategies. Herein, we report a case cardiomyopathy following single dose doxorubicin describe our pharmacologic approach. Case A 37 year old Jamaican male presented for work-up treatment HTLV-1 T-cell leukemia/lymphoma. Upon diagnosis, patient...
Background: Methotrexate (MTX) neurotoxicity (NT) is severe acute or subacute central NT with potential long-term neurologic sequelae that associated intrathecal (IT) intravenous (IV) administration of methotrexate chemotherapy. It characterized by stroke-like focal deficits, seizures, speech disturbance and encephalopathy. This adverse event (AE) estimated to occur in 3-7% children treated ALL, but some reports rates as high 18%. Most the information available about incidence, presentation...
Introduction: In a pivotal phase 2 randomized cohort, addition of polatuzumab vedotin (pola) to bendamustine and rituximab (BR) improved rate complete response (CR), progression-free survival (PFS), overall (OS) versus BR alone in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Our experience suggests many treated BR-pola off-trial receive fewer cycles have dose reductions or omissions potentially impacting response. Methods: We reviewed adults who received ≥ 1...